A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 Under Fasted Conditions in Healthy Adult Subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
70
Single-dose oral administration of AD-118 or AD-1181, according to randomized sequence.
H PLUS YANGJI HOSPITAL, Seoul
Seoul, South Korea
Area under the plasma concentration-time curve during dosing interval (AUCt)
AUCt of AD-118
Time frame: pre-dose (0hour) to 36hours
Maximum concentration of drug in plasma (Cmax)
Cmax of AD-118
Time frame: pre-dose (0hour) to 36hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.